journal
MENU ▼
Read by QxMD icon Read
search

Expert Review of Vaccines

journal
https://www.readbyqxmd.com/read/28644696/varicella-vaccination-the-global-experience
#1
Peter Wutzler, Paolo Bonanni, Margaret Burgess, Anne Gershon, Marco Aurélio Sáfadi, Giacomo Casabona
Introduction Varicella, although a frequently benign childhood disease, nevertheless represents a considerable health burden. WHO recommends including varicella vaccines in universal routine vaccination programs, and maintaining coverage >80%. Many countries have successfully introduced varicella vaccination and have benefited from lower disease burden, but many others have not adopted the vaccine. Reasons include cost commitment for a 'mild childhood disease' or concerns that vaccination will shift varicella to older age groups or increase herpes zoster incidence...
June 23, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28633549/an-update-on-zika-vaccine-developments
#2
Anna Durbin, Annelies Wilder-Smith
The devastating consequences of congenital Zika virus (ZIKV) infection led to a global response directed toward a better understanding of the epidemiology and pathogenesis of ZIKV and to efforts at vaccine development. As a result, there are currently 45 ZIKV vaccine candidates in development. Areas covered: Both traditional (purified inactivated, live attenuated, viral-vectored, recombinant sub-unit) and novel (DNA, self-replicating RNA, mRNA) vaccine platforms are being utilized. For emergency use, vaccines that are appropriate for women of child-bearing age (including pregnant women) are being developed...
June 21, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28608729/accelerating-tuberculosis-vaccine-trials-with-diagnostic-and-prognostic-biomarkers
#3
Stefan H E Kaufmann, January Weiner, Jeroen Maertzdorf
The most recent estimates on tuberculosis (TB) morbidity and mortality reveal that the global disease burden is even higher than previously assumed. Better drugs, diagnostics and vaccines are major requirements to control the ongoing TB pandemic. The high complexity of the infectious process and the underlying pathology, however, challenge elucidation of protective immune mechanisms at the various stages towards active TB disease, which need to be understood for rational design of novel intervention measures...
June 19, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28604122/blood-stage-malaria-vaccines-post-genome-strategies-for-the-identification-of-novel-vaccine-candidates
#4
Edward H Ntege, Eizo Takashima, Masayuki Morita, Hikaru Nagaoka, Tomoko Ishino, Takafumi Tsuboi
An efficacious malaria vaccine is necessary to advance the current control measures towards malaria elimination. To-date, only RTS,S/AS01, a leading pre-erythrocytic stage vaccine completed phase 3 trials, but with an efficacy of 28-36% in children, and 18-26% in infants, that waned over time. Blood-stage malaria vaccines protect against disease, and are considered effective targets for the logical design of next generation vaccines to improve the RTS,S field efficacy. Therefore, novel blood-stage vaccine candidate discovery efforts are critical, albeit with several challenges including, high polymorphisms in vaccine antigens, poor understanding of targets of naturally protective immunity, and difficulties in the expression of high AT-rich plasmodial proteins...
June 19, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28612631/genetically-attenuated-malaria-parasites-as-vaccines
#5
Ashley M Vaughan, Stefan H I Kappe
No abstract text is available yet for this article.
June 16, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28573913/the-immunogenicity-and-safety-of-gsk-s-recombinant-hepatitis-b-vaccine-in-adults-a-systematic-review-of-30-years-of-experience
#6
Caroline Van Den Ende, Cinzia Marano, Ayla Van Ahee, Eveline M Bunge, Laurence De Moerlooze
Engerix B (GSK HepB, GSK, Belgium) was the first recombinant hepatitis B virus vaccine to be licensed, and marked its 30(th) anniversary in 2016. Vaccination of adult populations against HBV is usually implemented on a risk-based approach with varying degrees of success. Confirmation of ongoing vaccine effectiveness requires monitoring the performance of HBV immunization as reported in individual studies, using systematic methods. Areas covered: We conducted a systematic review of the literature to summarize 30 years of immunogenicity and safety data for GSK HepB in adult populations...
June 14, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28548626/correlates-of-protection-for-inactivated-enterovirus-71-vaccine-the-analysis-of-immunological-surrogate-endpoints
#7
Wenbo Zhu, Pengfei Jin, Jing-Xin Li, Feng-Cai Zhu, Pei Liu
BACKGROUND: Inactivated Enterovirus 71 (EV71) vaccines showed significant efficacy against the diseases associated with EV71 and a neutralizing antibody (NTAb) titer of 1:16-1:32 was suggested as the correlates of the vaccine protection. This paper aims to further estimate the immunological surrogate endpoints for the protection of inactivated EV71 vaccines and the effect factors. METHODS: Pre-vaccination NTAb against EV71 at baseline (day 0), post-vaccination NTAb against EV71 at day 56, and the occurrence of laboratory-confirmed EV71-associated diseases during a 24-months follow-up period were collected from a phase 3 efficacy trial of an inactivated EV71 vaccine...
June 12, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28586278/the-immunogenicity-of-gsk-s-recombinant-hepatitis-b-vaccine-in-children-a-systematic-review-of-30-years-of-experience
#8
Caroline van den Ende, Cinzia Marano, Ayla van Ahee, Eveline M Bunge, Laurence De Moerlooze
The World Health Organization recommends hepatitis B virus (HBV) vaccines to be included in national immunization schedules everywhere, and has adopted the strategic goal of halting viral hepatitis as a major public health threat by 2030, under which vaccination plays a major role. Engerix™ B (GSK HepB, GSK, Belgium) was the first recombinant HBV vaccine to be licensed, and marked its 30(th) anniversary in 2016. Areas covered: We conducted a systematic review of the literature summarizing 30 years of immunogenicity and safety data for GSK HepB in children and adolescents...
June 6, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28581345/development-and-identification-of-a-new-vero-cell-based-live-attenuated-influenza-b-vaccine-by-a-modified-classical-reassortment-method
#9
Fan Yang, Lei Ma, Jian Zhou, Yinjie Wu, Jingxia Gao, Shaohui Song, Xingliang Geng, Qi Guo, Zhuofan Li, Weidong Li, Guoyang Liao
OBJECTIVE: The goal of this study was to generate a new Vero and cold-adapted live attenuated influenza B vaccine and evaluate its safety and immunogenicity with experiments in a guinea pig model. METHODS: A modified classical reassortment method was used to generate the new vaccine strain. The donor strain was B/Yunnan/2/2005Vca(B), and the parental virus strain was B/Brisbane/60/2008wt. After co-infection in Vero cells, the prepared antibody serum inhibited the donor strain growth, and screening conditions inhibited the candidate virus growth, which induced the growth of the new reassortant virus B/Brisbane/60/2008Vca(B) grow...
June 5, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28460594/a-trivalent-inactivated-influenza-vaccine-vaxigrip%C3%A2-summary-of-almost-50-years-of-experience-and-more-than-1-8-billion-doses-distributed-in-over-120-countries
#10
Margaret Haugh, Viviane Gresset-Bourgeois, Bérengère Macabeo, Anne Woods, Sandrine I Samson
Vaxigrip, a trivalent split-virion, inactivated vaccine available since 1968 has been in use longer than any other influenza vaccine. It is the most widely-used influenza vaccine, with more than 1.8 billion doses distributed in more than 120 countries. Areas covered: The significant body of evidence that confirms the efficacy, effectiveness, immunogenicity, and safety of Vaxigrip in healthy individuals of all ages and at-risk populations is summarized. The results from at least 15 randomized efficacy trials and 15 other studies have demonstrated that vaccination with Vaxigrip is efficacious against various clinical endpoints...
May 10, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28447884/do-micrornas-play-a-role-in-the-activity-of-plant-based-vaccines
#11
Sergio Rosales-Mendoza, Jorge A Salazar-González
An important trend in vaccinology is the development of oral vaccines based on genetically modified plants. Areas covered: Several studies have suggested that dietary microRNAs from plants and other organisms are bioavailable upon oral ingestion exerting biological events in the host such as the modulation of gene expression in several cell types. Since oral plant-based vaccines rely on whole cells as vaccine delivery vehicles, miRNAs could play a role in the immunogenic activity of this type of vaccine. In the present report, this hypothesis is discussed under the light of recent evidence on the immunomodulatory activity exerted by miRNAs using in vitro and in vivo evaluations...
May 9, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28437234/poliovirus-vaccination-during-the-endgame-insights-from-integrated-modeling
#12
Radboud J Duintjer Tebbens, Kimberly M Thompson
Managing the polio endgame requires access to sufficient quantities of poliovirus vaccines. After oral poliovirus vaccine (OPV) cessation, outbreaks may occur that require outbreak response using monovalent OPV (mOPV) and/or inactivated poliovirus vaccine. Areas covered: We review the experience and challenges with managing vaccine supplies in the context of the polio endgame. Building on models that explored polio endgame risks and the potential mOPV needs to stop outbreaks from live poliovirus reintroductions, we conceptually explore the potential demands for finished and bulk mOPV doses from a stockpile in the context of limited shelf-life of finished vaccine and time delays to convert bulk to finished vaccine...
May 9, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28434256/a-bioinformatics-roadmap-for-the-human-vaccines-project
#13
Richard H Scheuermann, Robert S Sinkovits, Theodore Schenkelberg, Wayne C Koff
Biomedical research has become a data intensive science in which high throughput experimentation is producing comprehensive data about biological systems at an ever-increasing pace. The Human Vaccines Project is a new public-private partnership, with the goal of accelerating development of improved vaccines and immunotherapies for global infectious diseases and cancers by decoding the human immune system. To achieve its mission, the Project is developing a Bioinformatics Hub as an open-source, multidisciplinary effort with the overarching goal of providing an enabling infrastructure to support the data processing, analysis and knowledge extraction procedures required to translate high throughput, high complexity human immunology research data into biomedical knowledge, to determine the core principles driving specific and durable protective immune responses...
May 9, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28447498/regulating-vaccines-at-the-fda-development-and-licensure-of-zika-vaccines
#14
Marion F Gruber, Philip R Krause
No abstract text is available yet for this article.
May 4, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28431490/new-challenges-in-therapeutic-vaccines-against-hiv-infection
#15
Lorna Leal, Constanza Lucero, Josep M Gatell, Teresa Gallart, Montserrat Plana, Felipe García
There is a growing interest in developing curative strategies for HIV infection. Therapeutic vaccines are one of the most promising approaches. We will review the current knowledge and the new challenges in this research field. Areas covered: PubMed and ClinicalTrial.gov databases were searched to review the progress and prospects for clinical development of immunotherapies aimed to cure HIV infection. Dendritic cells (DC)-based vaccines have yielded the best results in the field. However, major immune-virologic barriers may hamper current vaccine strategies...
May 4, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28425834/rift-valley-fever-vaccines-an-overview-of-the-safety-and-efficacy-of-the-live-attenuated-mp-12-vaccine-candidate
#16
Tetsuro Ikegami
Rift Valley fever (RVF) is a mosquito-borne zoonotic viral disease endemic to Africa and the Arabian Peninsula. High rates of abortion among infected ruminants and hemorrhagic fever in infected humans are major public health concerns. Commercially available veterinary RVF vaccines are important for preventing the spread of the Rift Valley fever virus (RVFV) in endemic countries; however, RVFV outbreaks continue to occur frequently in endemic countries in the 21st century. In the U.S., the live-attenuated MP-12 vaccine has been developed for both animal and human vaccination...
May 2, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28409537/impact-of-pneumococcal-conjugate-vaccines-for-children-in-high-and-non-high-income-countries
#17
Robert Cohen, Jérémie François Cohen, Martin Chalumeau, Corinne Levy
The high level of effectiveness of pneumococcal conjugate vaccines (PCVs) was demonstrated initially in high-income countries (HICs). However, because the burden of pneumococcal diseases (PDs) is greater in non-high-income countries (NHICs) than HICs, the assessment of these vaccines in this latter setting is crucial. Areas covered: PubMed was used to search for literature related to the effectiveness of PCVs. Several studies described the effectiveness of PCVs in NHICs, and we compare the impact of PCVs on the incidence of invasive pneumococcal disease (IPD) and pneumonia in HICs and NHICs...
April 28, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28322076/closer-than-ever-to-an-ebola-virus-vaccine
#18
Logan Banadyga, Andrea Marzi
No abstract text is available yet for this article.
April 3, 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28635341/erratum
#19
(no author information available yet)
No abstract text is available yet for this article.
July 2017: Expert Review of Vaccines
https://www.readbyqxmd.com/read/28590795/a-recombinant-live-attenuated-tetravalent-vaccine-for-the-prevention-of-dengue
#20
Bruno Guy, Fernando Noriega, R Leon Ochiai, Maïna L'azou, Valentine Delore, Anna Skipetrova, François Verdier, Laurent Coudeville, Stephen Savarino, Nicholas Jackson
Dengue is an important and still growing public health problem associated with substantial morbidity, as well as significant social and economic impact. The present review describes the main features and development of the first dengue vaccine (CYD-TDV, Dengvaxia®), which has been licensed by several dengue-endemic countries in Asia and Latin America for use in populations above 9 years of age. Areas covered: The review focuses on the large clinical development of CYD-TDV, which includes in particular two pivotal phase III efficacy trials conducted in Asia and Latin America and supported vaccine licensure...
July 2017: Expert Review of Vaccines
journal
journal
40291
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"